The increasing number of patients suffering from acute sinusitis are expected to boost the growth of the Global Acute Sinusitis Market at a CAGR of 7.50 % during the forecast period of 2022 to 2030

Market Research Future (MRFR) has published a cooked research report on the “Global Acute Sinusitis Market” that contains the information from 2022 to 2030.

The Acute Sinusitis Market is expected to reach USD 2.15 Billion by 2030 at 7.50% CAGR during the forecast period 2022-2030

MRFR recognizes the following companies as the key players in the Global Acute Sinusitis Market— Sanofi (France), Abbott (US), Bayer AG (Germany), Aurobindo Pharma (India), Bristol Myers Squibb (US), Merck KGaA (Germany), AstraZeneca (UK), Dr. Reddy’s Laboratories, Ltd (India), Novartis AG (Switzerland), and GlaxoSmithKline plc (UK), among others.

Market Highlights

Acute sinusitis is an infection of the mucous membrane of the paranasal sinuses, which surround the nasal cavity, that lasts only a few days. This common condition causes nasal discharge, nasal blockage, sneezing, pain, facial pressure, and edoema across the affected area. Headache, sinus, cough, chills, fever, and hyposmia are some of the other symptoms.

The growth of the global acute sinusitis market is expected to be driven by factors Increasing number of patients suffering from acute sinusitis and availability of several treatment and diagnostic options. Moreover, the expanding number of people suffering from acute sinusitis, as well as the extensive range of treatment and diagnostic options available, are driving market expansion. On the other hand, the market's progress is hampered by a lack of awareness about acute sinusitis. Increased global R&D and healthcare spending, is expected to provide growth prospects for global market leaders.

Segment Analysis

The global acute sinusitis market is mainly segmented into diagnosis & treatment, and end user. On the basis of diagnosis, the market has been bifurcated into nasal endoscopy, imaging test, laboratory test, allergy testing) whereas treatment is further categorized into nasal corticosteroids, decongestants, OTC pain relievers, allergy shots, antibiotics). On the basis of end user, the market is further segmented into hospitals & clinics, research centers, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Acute Sinusitis Market Research Report

Regional Analysis

The global acute sinusitis market has been segmented based on region into Americas, Europe, Asia Pacific, and Middle East & Africa. The Americas region held the largest market share of 36.77% in the year 2020 and is anticipated to dominate the overall global acute sinusitis market throughout the study period. Whereas the Asia Pacific region is expected to exhibit the highest CAGR from 2021 to 2027.

The major factors driving America's Acute Sinusitis Market include the presence of key players operating in this region and growing awareness related to acute sinusitis in the region. Additionally, the major players present in the region are driving growth for the market through product innovations, collaborations, acquisitions, and expansions.

Europe held the second-largest market share in 2020. The factors that drive market growth in the region are rising prevalence of sinusitis and increasing geriatric population. Moreover, increasing initiatives by the government in the region for awareness of sinusitis is also influencing the market growth. Recently, in February 2020, European and International Rhinologic Societies published European Position Paper on Rhinosinusitis and Nasal Polyphs 2020 (EPOS2020), which provides revised, up-to-date, and transparent, evidence-based recommendations and guidelines in acute rhinosinusitis and chronic rhinosinusitis. According to EPOS2020, acute rhinosinusitis has a one-year prevalence of 6–15% and is usually the consequence of a viral common cold. Therefore, the rising prevalence demands safe and effective treatment and diagnosis options. In addition, increasing healthcare expenditure and research funding coupled with the rising number of clinical trials has further boosted the market growth.

Asia Pacific is the fastest-growing regional market for acute sinusitis market with an estimated CAGR of 10.07% during the forecast. This is owing to the improving healthcare infrastructure and the increasing number of patients suffering from acute sinusitis, which is stimulating the need for the adoption of acute sinusitis medications. Moreover, the key players are expanding their presence in the region to diagnose and treat acute sinusitis. For instance, in December 2020, GlaxoSmithKline plc (UK) launched Otrivin Breathe Clean, a saline nasal wash for maintaining nasal hygiene in India. Likewise, in June 2020, Dr. Reddy’s Laboratories, Ltd. (India) acquired Wockhardt’s branded generics business in India and a few other international territories, including Nepal, Sri Lanka, Bhutan, and the Maldives. The acquired business comprises a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, VMS, dermatology, gastroenterology, pain, and vaccines. These factors are driving the growth of the acute sinusitis market in Asia-Pacific.

The market for acute sinusitis is growing in the Middle East & Africa due to the increasing geriatric population in the Middle Eastern countries and increasing healthcare spending in the region. Moreover, the increasing number of research companies and subsidiaries involved in R&D, rising initiatives taken by the Middle East countries to develop their healthcare infrastructure, growing awareness, and demand from the general population for effective treatments is likely to favour the market growth. Middle Eastern countries such as the UAE and Kuwait are anticipated to contribute to strengthening the regional market growth owing to their economic stability.

Key Findings of the Study

• The global acute sinusitis market is expected to reach USD 3,319.41 million by 2027 at a CAGR of 7.89% during the forecast period.


• Based on diagnosis & treatment type, the treatment segment accounted for the largest market share of 63.53% in 2020.


• Based on end user, the hospital & clinics segment dominated the market with a share of 57.49% in 2020.


• The Americas region accounted for the largest share of the global market by region, which is majorly attributed to the presence of key players operating in this region and growing awareness related to acute sinusitis.


• Some of the key players operating in the Global Acute Sinusitis Market are Sanofi (France), Abbott (US), Bayer AG (Germany), Aurobindo Pharma (India), Bristol Myers Squibb (US), Merck KGaA (Germany), AstraZeneca (UK), Dr. Reddy’s Laboratories (India), Novartis AG (Switzerland), and GlaxoSmithKline plc (UK), among others.